E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Low Molecular Weight Heparin (LMWH) thromboprophylaxis in patients with COVID-19 |
|
E.1.1.1 | Medical condition in easily understood language |
Prevention of blood clots in patients with a COVID-19 infection |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
We want to find out if giving a small dose of blood-thinning drug (enoxaparin) in an early stage of the COVID-19 disease can prevent the individuals being admitted to hospital and/or death.
Half the patients in the study will receive enoxaparin for three weeks in addition to standard of care, and half will receive only standard of care treatment (no enoxaparin). Individuals will be randomly allocated to one of these groups. After 21 days, the number of patients in each group who were either admitted to hospital, or died, will be compared. |
|
E.2.2 | Secondary objectives of the trial |
We want to find out if giving a small dose of blood-thinning drug (enoxaparin) in an early stage of the COVID-19 disease can prevent patients being given extra oxygen as treatment for the disease, developing a blood clot or having a stroke within 21 days after receiving the drug. The two groups will be compared again at 50 and 90 days.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Signed Informed consent Confirmed COVID-19 (i.e. symptoms + positive test for SARS-CoV-2) Male or female, age ≥ 55 years At least two of the following additional risk factors: o Age ≥ 70 years o Body mass index > 25 kg/m2 o Chronic obstructive pulmonary disease (COPD)* o Diabetes* o Cardiovascular disease* o Corticosteroid use *Defined as any disease requiring medical intervention or treatment |
|
E.4 | Principal exclusion criteria |
Contraindications to unfractionated heparin or LMWH Recent (<48 hours) or planned spinal or epidural anesthesia or puncture, PCI or thrombolytic therapy within the preceding 24 hours Increased risk for bleeding complications Pregnant women Severe renal impairment (GFR < 30 mL/min) Receiving any antiplatelet therapy (with the exception of low dose (≤100mg) aspirin) or anticoagulant therapy (e.g. VKA, DOAC) Patients participating in an interventional study that is outside the purview of TRI sponsored studies. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of this study will be the composite of hospitalization or all-cause death within 21,50 and 90 days after randomization. • Death • All-cause • Cardiovascular • Non-Cardiovascular • Specific causes • Fatal bleed • Hospital admission o Pneumonia o Acute Respiratory distress syndrome o Acute medical care or admission to intensive care unit (ICU) o Mechanical ventilation/ Extracorporeal membrane oxygenation (ECMO) o Non-invasive ventilation/high flow oxygen o Hospitalized on supplemental oxygen o Hospitalized not requiring supplemental oxygen o Hospitalized not requiring ongoing medical care
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
21,50 and 90 days after randomization |
|
E.5.2 | Secondary end point(s) |
• Bleeding (as defined by ISTH criteria) (at 21 and 50 days) o Frequency o Location o Treatment (transfusion and units of blood products transfused) o Severity (classified as major, clinically relevant non-major and minor • Diagnosis of VTE: Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) (at 21, 50 and 90 days)
• Diagnosis of Ischemic stroke (at 21, 50, and 90 days)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Bleeding (as defined by ISTH criteria) (at 21 and 50 days) Diagnosis of VTE: Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) (at 21, 50 and 90 days) Diagnosis of Ischemic stroke (at 21, 50, and 90 days) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Standard of care treatment not mandated by protocol |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Brazil |
India |
South Africa |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 15 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 8 |